Drugs / Umeclidinium/vilanterol
Umeclidinium/vilanterol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02487446 | Jul 2015 → Sep 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umeclidinium/vilanterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02487446 ↗ |
| Known as | UMEC/VI | “PURPOSE: To compare the efficacy and safety of two long-acting dual bronchodilator combinations: indacaterol/glycopyrrolate (IND/GLY) versus umeclidinium/vilanterol (UMEC/VI).” PMID 28993871 ↗ Oct 2017 |
| Known as | Umeclidinium Bromide/Vilanterol | “Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: ” PMID 28993871 ↗ Oct 2017 |
| Route | Inhaled | “Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily” NCT02487446 ↗ |